Plan-B: Exploring Alternative Preventive Medications for Migraines and Chronic Headaches: Comprehensive Literature Review and Analysis of Efficacy and Practical Considerations for Non-First- Line Treatments

Anjaneya Shankar Madhav Bandatmakur^*1, Sindhura Tadisetty², Prasanna Kumar Gangishetti³

*Correspondence to: Anjaneya Shankar Madhav Bandatmakur, USA.

Copyright

© 2025: Anjaneya Shankar Madhav Bandatmakur. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 17 Sep 2025

Published: 01 Oct 2025

 

Chronic headaches, including chronic migraine, chronic daily headache (CDH), new daily persistent headache (NDPH), and chronic post-traumatic headache, represent a significant public health issue due to their high prevalence, associated disability, and economic burden. Epidemiological studies estimate that chronic migraine affects approximately 2% of the population, while CDH affects about 4% to 5% of the general population. 1, 2 These conditions are marked by frequent and severe headache episodes, leading to significant impairment in daily functioning and quality of life. 1-3

Demographic data show that these headache disorders differ notably between adult and pediatric populations. Chronic migraine and NDPH are increasingly recognized as major contributors to disability in children and adolescents. A study revealed that over 25% of U.S. adolescents experience frequent or severe headaches, comparable in impact to chronic conditions like arthritis. 4 NDPH often begins abruptly, often triggered by physical or psychological stress, and is more common in younger populations, particularly during school transitions. 5 On the other hand, chronic migraine usually evolves from episodic migraine, with a gradual increase in frequency, often worsened by comorbid conditions such as anxiety and depression. 1, 2, 6

The burden of chronic headaches extends beyond individual suffering, imposing significant economic costs on society. Chronic migraine, for example, is associated with high levels of absenteeism and presenteeism, leading to lost productivity and increased healthcare costs. 3, 7 A national survey in Brazil reported a migraine prevalence of 15.2%, with a substantial portion of the population experiencing daily headaches. 8 This underscores the need for effective management strategies and preventive treatments to reduce the impact on both individuals and healthcare systems.

Comparative studies across different regions and populations have shown variations in the prevalence of chronic headaches. In a large population-based study in Denmark, researchers examined the comorbidity of migraine with other somatic diseases, revealing a complex interplay between genetic and environmental factors predisposing individuals to chronic headache disorders. 9 Geographic factors also influence migraine prevalence; for example, higher rates are reported in southern regions of China compared to northern areas, suggesting that climate and lifestyle may play a role in headache epidemiology. 10

Gender differences are also significant in chronic headache demographics. Women are disproportionately affected by migraines, particularly during their reproductive years, with hormonal fluctuations contributing to the frequency and severity of attacks. 11 This gender disparity is further complicated by comorbid conditions, such as anxiety and depression, which are more prevalent in women and can exacerbate headache symptoms. 1, 2 Understanding these demographic factors is crucial for tailoring treatment approaches to improve outcomes.

In pediatric populations, chronic migraine and NDPH are often underdiagnosed and undertreated, despite their significant impact on quality of life and daily functioning. 6, 12 Research indicates that children with chronic migraine experience severe functional disability, similar to that seen in adults, underscoring the importance of early diagnosis and intervention. 6 transition from episodic to chronic migraine during adolescence is a critical period that warrants attention, as effective management during this time can alter the disorder's trajectory. 13

The epidemiology of chronic headaches highlights the importance of considering comorbidities and their impact on treatment outcomes. Individuals with chronic migraine often report higher levels of disability and poorer quality of life compared to those with episodic migraine, emphasizing the need for comprehensive treatment strategies that address both headache management and associated comorbid conditions. 1-3 Additionally, medication overuse headache (MOH), which frequently accompanies chronic headache disorders, complicates treatment and requires careful management to avoid exacerbating symptoms. 14

Recent advancements in treatment options, such as the introduction of novel preventive medications like calcitonin gene-related peptide (CGRP) monoclonal antibodies, offer new hope for individuals suffering from chronic headaches. 3, 7 However, barriers to accessing these treatments, including lack of awareness and healthcare disparities, continue to hinder optimal care for many patients. 2, 3 Addressing these barriers is essential for improving outcomes and reducing the burden of chronic headaches.

 

Barriers to Effective Treatment

The treatment of chronic headaches is often hindered by various barriers, including healthcare access, patient- related factors, treatment-related challenges, and systemic issues within healthcare systems. Understanding these barriers is crucial for developing effective interventions to improve treatment outcomes for individuals suffering from these debilitating conditions.

One significant barrier is limited access to healthcare services. Many patients with chronic headaches face challenges in obtaining timely and appropriate medical care, especially in rural or underserved areas where specialized headache clinics may not be available. 15, 16 Furthermore, the stigma associated with chronic pain conditions can deter individuals from seeking help, as they may fear being perceived as exaggerating their symptoms or being labeled as "difficult" patients. 17, 18 This stigma is particularly pronounced in populations like military personnel, where there are additional concerns about the implications of reporting chronic pain on career advancement and mental health evaluations. 16, 18

Patient-related factors also play a significant role. Many individuals with chronic headaches may lack awareness regarding their condition and the available treatment options, leading to underreporting of symptoms and delays in seeking care. 19 Comorbid psychiatric conditions, such as anxiety and depression, are prevalent among chronic headache sufferers and can complicate treatment adherence and outcomes. For example, patients with chronic migraine who also suffer from depression may experience higher levels of disability and poorer treatment responses, further complicating their management. 20

Treatment-related challenges include inadequate responses to first-line preventive medications, leading to frustration and a sense of hopelessness regarding treatment options. 17, 21 MOH is particularly concerning, as it can develop in patients who frequently use acute headache medications, leading to a cycle of increased headache frequency and severity. 22, 23 This cycle complicates treatment and requires a careful, often challenging approach to medication management, which may not be adequately addressed in standard clinical practice. 24

The complexity of chronic headache disorders themselves can hinder effective treatment. Chronic headaches are often heterogeneous, with overlapping symptoms and varying responses to treatment among individuals.

25 For instance, patients with chronic migraine and those with chronic tension-type headache may respond differently to the same treatment regimen, necessitating a personalized approach that can be resource- intensive and time-consuming. 19, 25 Additionally, the presence of CDH can complicate the treatment of primary headache disorders, as patients may require a multimodal approach that addresses both the headache and any underlying psychological or behavioral issues. 20

Systemic issues within healthcare systems exacerbate these barriers. Many healthcare providers lack specialized training in headache management, leading to suboptimal treatment recommendations and reliance on trial-and-error approaches. 25 This lack of expertise can result in delays in diagnosis and treatment, as well as increased healthcare costs due to unnecessary testing and ineffective treatments. 25 The fragmentation of care, where patients see multiple providers without coordinated management, can lead to confusion and frustration for patients seeking effective treatment. 25

Insurance coverage and reimbursement policies also impact access to care. Many insurance plans impose restrictions on the types of treatments covered, limiting access to newer and potentially more effective therapies. 19 The high cost of certain treatments, such as monoclonal antibodies for migraine prevention, can be prohibitive for many patients, particularly those without adequate insurance coverage. 22, 26 This financial burden can lead to treatment abandonment, further exacerbating the cycle of chronic headache and disability.

Need for Alternative Treatment Options

The treatment landscape for chronic headaches, particularly migraines, presents significant challenges, necessitating the exploration of alternative treatment options. One primary barrier is medication overuse, leading to MOH, particularly among chronic migraineurs. Over-prescription of opioids for acute migraine treatment has been noted, with studies indicating that nearly one in four chronic migraine patients may develop MOH. 27 This cycle of overuse complicates treatment and highlights the urgent need for alternative strategies that can mitigate MOH risk while effectively managing headache symptoms.

The pediatric population faces unique challenges in accessing approved treatments for chronic headaches. Many pharmacological options available for adults are not yet approved for use in children and adolescents, leaving healthcare providers with limited choices for managing migraines in younger patients. 28, 29 This lack of approved treatments underscores the importance of exploring non-pharmacological interventions and alternative therapies. For instance, acupuncture has shown promise in reducing headache frequency and severity, providing a viable alternative for those who may not tolerate traditional medications well. 30 Behavioral interventions, such as biofeedback therapy, have also demonstrated efficacy in reducing headache days in children, emphasizing the need for diverse treatment modalities. 31

Integrating alternative treatment options is essential for addressing medication-related barriers, improving overall treatment adherence, and enhancing patient satisfaction. Compliance with traditional prophylactic medications is a significant issue, with many patients discontinuing treatment within three months due to side effects or lack of efficacy. 2 In contrast, treatments like onabotulinumtoxinA, which require less frequent administration, have shown better adherence rates. 2 This highlights the potential for alternative therapies to enhance patient engagement and improve outcomes.

Furthermore, innovative treatment modalities, such as neuromodulation techniques, offer promising possibilities for managing chronic headaches. Non-invasive vagus nerve stimulation (nVNS) and direct current stimulation have shown promise in reducing headache frequency and severity, providing additional options for patients who may not respond well to conventional pharmacological treatments. 17, 32 These emerging therapies could play a crucial role in the comprehensive management of chronic headaches, particularly for those with medication-related barriers.

Preventive therapy for migraines aims to reduce the frequency of headache episodes, diminish migraine- related disability, improve quality of life, and manage the need for acute medications. The complexity of these therapies arises from the need for slow titration, gradual weaning, and sometimes combination therapies, complicating management for both patients and healthcare providers. 33, 34

 

Migraine Migraine preventive therapies are classified into four levels of evidence:

• Level A: Strong evidence supports treatments like sodium valproate, topiramate, metoprolol, propranolol, timolol, and onabotulinumtoxinA for chronic migraines. 33, 35, 36

• Level B: Moderate evidence supports treatments like amitriptyline and venlafaxine. 33, 34

• Level C: Limited evidence supports treatments like candesartan, lisinopril, and cyproheptadine. 33, 34

• Level U: Uncertain or conflicting evidence supports treatments like gabapentin and verapamil.33, 34

 

Despite the availability of these treatments, the pediatric population faces unique challenges in accessing approved therapies for chronic migraines. Many pharmacological options available for adults are not yet approved for use in children and adolescents, leaving healthcare providers with limited choices. 37 This lack of approved treatments underscores the importance of exploring non-pharmacological interventions and alternative therapies, such as biofeedback, which has shown promise in reducing headache frequency and severity. 38

The need for alternative treatment options is driven by the limitations of current therapies. Compliance with prescribed therapies is a major issue, as many patients struggle with dosing frequency, leading to missed doses and inconsistent adherence. 39, 40. Side effects can lead to discontinuation or require dose adjustments, complicating treatment. The commitment required for dosing, titration, and the slow escalation and weaning process adds another layer of complexity, particularly for patients who may not see immediate results. 41

Additionally, contraindications due to other medical conditions and potential interactions with other medications can limit treatment options. Frequent monitoring is necessary to manage potential toxicity and interactions, complicating the overall process. Treatment failure, especially after trying multiple first-line agents, underscores the necessity for alternative options, as there is no one-size-fits-all approach to migraine management. This is particularly true in pediatric populations, where response rates to treatments can vary widely, and medication side effects may be more pronounced.42, 43

Cost is another significant barrier, especially in pediatric populations where approved options are limited. The financial burden of off-label or alternative therapies can be prohibitive for many families. 44 Access to these medications can also be challenging, particularly in remote areas where pharmacies may not carry specialized treatments. Insurance coverage poses an additional hurdle, as many alternative treatments are off-label and may require patients to fail prior treatments before coverage is approved. 45, 46

Patient preferences also play a crucial role in the need for alternative therapies. Some patients may have specific aversions to certain delivery methods, such as needles, nasal sprays, or the taste of melting tablets. Allergies, needle phobia, and an unwillingness to undergo infusions further complicate treatment choices. 47These factors highlight the necessity for a broader range of treatment options to effectively manage migraines and chronic headaches.

In managing migraines and chronic headaches, exploring alternative preventive treatments has become increasingly important due to the limitations and challenges associated with first-line therapies. This review highlights several alternative medications that may be considered for the preventive treatment of migraines and chronic headaches, including acetazolamide, candesartan, caffeine, cannabinoids, corticosteroids (dexamethasone, prednisone), cyproheptadine, doxycycline, duloxetine, furosemide, gabapentin, indomethacin, ketamine, lamotrigine, levetiracetam, lisinopril, low dose naltrexone, memantine, mixelitine, monteleukast, muscle relaxants (baclofen, cyclobenzaprine, tizanidine), neuroleptics, pregabalin, venlafaxine, verapamil, and zonisamide.

Despite FDA-approved therapies, significant challenges persist, driving the need for these alternative options. Compliance with prescribed therapies is a major concern, as many patients struggle with dosing frequency, leading to missed doses and inconsistent adherence. 39, 40 Side effects can lead to discontinuation or require dose adjustments, complicating treatment. The commitment required for dosing, titration, and the slow escalation and weaning process adds another layer of complexity to migraine management, particularly for patients who may not see immediate results. 41

Contraindications due to other medical conditions and potential interactions with other medications can limit the use of certain treatments. Frequent monitoring is often necessary to manage potential toxicity and interactions, complicating the overall treatment process. 48 Treatment failure, especially after trying multiple first-line agents, underscores the necessity for alternative options, as there is no one-size-fits-all approach to migraine management. This is particularly true in pediatric populations, where response rates to treatments can vary widely.42, 49

Cost is another significant barrier, particularly in pediatric populations where approved options are limited. The financial burden of off-label or alternative therapies can be prohibitive for many families. 44 Access to these medications can also be challenging, especially in remote areas where pharmacies may not carry specialized treatments. Insurance coverage poses an additional hurdle, as many alternative treatments are off-label and may require patients to fail prior treatments before coverage is approved. 45, 46

Patient preferences also play a crucial role in the need for alternative therapies. Some patients may have specific aversions to certain delivery methods, such as needles, nasal sprays, or the taste of melting tablets. Allergies, needle phobia, and an unwillingness to undergo infusions further complicate treatment choices. 47 These factors highlight the necessity for a broader range of treatment options to effectively manage migraines and chronic headaches.

 

Acetazolamide

Acetazolamide is a carbonic anhydrase inhibitor primarily used to treat conditions like glaucoma, epilepsy, and altitude sickness, but it has also gained attention for its role in managing headaches and migraines, particularly in pediatric populations. The drug's mechanism of action involves inhibiting carbonic anhydrase, an enzyme that helps regulate acid-base balance and fluid secretion in the body. By inhibiting this enzyme, acetazolamide reduces the production of cerebrospinal fluid (CSF), leading to a decrease in intracranial pressure (ICP). This reduction in ICP is particularly beneficial in conditions like idiopathic intracranial hypertension (IIH), where elevated ICP is a significant contributor to headache symptoms.50-52

In clinical studies, acetazolamide has been shown to effectively alleviate headaches associated with IIH by reducing the severity of headaches and stabilizing visual function. Improvements in quality-of-life measures and reductions in headache disability scores have been reported. 50-52 In pediatric populations, acetazolamide has demonstrated promise in treating headaches associated with conditions like pseudotumor cerebri. A retrospective study indicated that a significant proportion of children responded positively to acetazolamide, with 37.8% to 76.6% of patients experiencing relief from headaches and associated symptoms. 53, 54

The treatment is often continued until symptoms such as papilledema and visual disturbances resolve, underscoring the importance of monitoring in this demographic. The dosing of acetazolamide varies depending on the condition being treated and the age of the patient. For adults, doses can range from 250 mg to 1000 mg per day, while pediatric dosing typically requires careful adjustment based on weight and clinical response. 51, 55 The drug is generally well-tolerated, but common side effects include metabolic acidosis, hypokalemia, paresthesia, and gastrointestinal disturbances, which can impact patient adherence to treatment. 56, 57

Additionally, the incidence of nephrolithiasis (kidney stones) has also been reported in patients receiving acetazolamide, highlighting the need for monitoring renal function during treatment. 58

The vasodilatory properties of acetazolamide further contribute to its therapeutic effects in headache management. Research indicates that acetazolamide can reverse cerebral vasoconstriction, a phenomenon often implicated in migraine pathophysiology. 59 This dual action—reducing ICP while promoting vasodilation— positions acetazolamide as a versatile option in the management of headaches, particularly in patients with complex presentations such as IIH or migraines associated with altitude changes. 55, 59

 

Caffeine

Caffeine is one of the most widely consumed psychoactive substances globally, with a significant presence in coffee, tea, soft drinks, and certain medications. Its role in headache and migraine management is complex and multifaceted. On one hand, caffeine is known to be a potential trigger for headaches and migraines, especially when consumed in large quantities or irregularly. On the other hand, caffeine can also be used therapeutically to relieve headaches, particularly when combined with other analgesics.

In pediatric populations, research indicates that caffeine consumption is associated with an increased prevalence of headaches, particularly among children and adolescents who consume high amounts of caffeine daily. A study highlighted that caffeine-induced daily headaches are prevalent in younger populations, with evidence suggesting a causal relationship between high caffeine intake and migraine occurrences in children and adolescents. 60 This underscores the need for careful monitoring of caffeine consumption in this demographic, as excessive intake may exacerbate headache conditions.

The mechanisms through which caffeine exerts its effects on headache and migraine pathophysiology are primarily associated with its action as a non-selective antagonist of adenosine receptors, particularly A1 and A2A receptors. This antagonistic action can lead to vasoconstriction of cerebral blood vessels, which is beneficial during a migraine attack, as it counteracts the vasodilation that typically occurs during such episodes. 61 Additionally, caffeine enhances the analgesic effects of other medications, such as acetaminophen and aspirin, making it a valuable adjuvant in headache treatment protocols. 62 The combination of these analgesics with caffeine has been classified as a first-line option for acute migraine management by the American Headache Society, indicating its clinical significance. 63

However, the relationship between caffeine and headaches is complex, as excessive caffeine consumption can also lead to withdrawal headaches when intake is abruptly reduced. Studies have shown that caffeine withdrawal can trigger migraine attacks, suggesting that individuals who consume caffeine regularly may develop a dependency that complicates their headache management. 64 This phenomenon is particularly relevant in pediatric populations, where the developing nervous system may respond differently to caffeine compared to adults. The withdrawal symptoms can include rebound headaches, which may further complicate the clinical picture for young patients. 65

In terms of dosing, the effects of caffeine on headache management appear to be dose-dependent. Moderate caffeine intake has been associated with a reduction in headache frequency and intensity, while high doses may lead to increased headache prevalence. 66 For instance, a study noted that caffeine consumption correlates positively with both episodic and chronic migraine, indicating that while caffeine can be beneficial in acute scenarios, it may also contribute to the chronicity of headache disorders if consumed excessively. 67 Pediatric studies suggest that caffeine intake should be carefully regulated, as children may be more susceptible to the adverse effects of high caffeine consumption, including increased headache frequency and severity. 60

Common side effects associated with caffeine consumption include insomnia, increased heart rate, and gastrointestinal disturbances, which can be particularly concerning in pediatric populations. These side effects may not only affect the child's overall health but also their academic performance and social interactions, further complicating the management of headaches in this demographic. 68 Therefore, healthcare providers must weigh the potential benefits of caffeine as a therapeutic agent against its risks, especially in younger patients who may have different tolerances and responses to caffeine compared to adults.

 

Candesartan

Candesartan, an angiotensin II receptor blocker (ARB), has gained recognition as a potential migraine prophylactic agent. It is particularly noteworthy in pediatric populations, although its application in this demographic remains limited compared to adults. Recent findings from a retrospective cohort study indicated that candesartan is well-tolerated and may significantly reduce the mean monthly headache days in adolescents with high baseline headache frequency. This study included adolescents suffering from various headache disorders, such as chronic migraine and medication-overuse headaches. The results demonstrated a notable reduction in headache days post-treatment, suggesting that earlier intervention with candesartan could yield better outcomes. The study also reported only mild side effects, reinforcing the drug's safety profile in younger patients. 69, 70

The efficacy of candesartan in migraine prevention was first substantiated in a randomized, double-blind, placebo-controlled crossover study conducted in Norway in 2003. This pivotal trial revealed that candesartan significantly decreased both the frequency and severity of headaches compared to placebo, establishing its role as an effective prophylactic agent. The study concluded that candesartan’s tolerability was comparable to that of placebo, making it a viable option for patients seeking migraine management. 71 Subsequent studies have corroborated these findings; for instance, a 2019 retrospective cohort study reported that a substantial proportion of patients with chronic migraine or medication-overuse headaches experienced at least a 50% reduction in headache frequency following. 72

Systematic reviews and meta-analyses have further emphasized the potential of ARBs, including candesartan, in mitigating headache days and severity. A 2010 review highlighted that candesartan's efficacy in migraine prophylaxis is comparable to that of other commonly used agents, particularly benefiting patients with comorbid conditions such as hypertension. 73 Another review noted that while candesartan and other ARBs are effective for migraine prevention, they are not typically recommended as first-line treatments. However, they can be particularly useful for patients with concurrent health issues. 74

In a comparative study conducted in 2013, candesartan was shown to be non-inferior to propranolol, a well- established migraine prophylactic, in reducing migraine days per month. Both medications significantly outperformed placebo, with candesartan demonstrating efficacy similar to that of propranolol. 75 Real-world evidence further supports the notion that candesartan can benefit difficult-to-treat migraine patients, especially those who are younger or have a longer disease duration. The study indicated that daily headaches were associated with a lower likelihood of treatment success, underscoring the need for tailored therapeutic approaches. 69

Despite the promising evidence in adult populations, the application of candesartan in pediatric settings remains underexplored. A recent review underscored the urgent need for more migraine trials focusing on children and adolescents, as existing literature predominantly centers on adult populations. 76 Nevertheless, emerging findings suggest that candesartan could serve as a viable option for migraine prevention, even in patients who have previously failed multiple treatments. Overall, while candesartan is not yet universally recognized as a first-line treatment in most clinical guidelines, its efficacy and tolerability render it a compelling option, particularly for patients with coexisting hypertension or cardiovascular conditions.

The mechanism of action of candesartan involves the blockade of the angiotensin II type 1 receptor, which plays a crucial role in the regulation of blood pressure and fluid balance. By inhibiting this receptor, candesartan not only lowers blood pressure but may also exert neuroprotective effects that could contribute to its efficacy in migraine prevention. Common side effects associated with candesartan include dizziness, fatigue, and hypotension, although these are generally mild and transient. The typical dosing for migraine prophylaxis starts at 8 mg daily, with adjustments made based on patient response and tolerability.

 

Cannabinoids

The exploration of cannabinoids, such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), as preventive options for headaches and migraines, particularly in pediatric populations, is gaining traction in contemporary medical research. Cannabinoids interact with the endocannabinoid system (ECS), which plays a crucial role in pain modulation. Recent studies indicate that the ECS components, including cannabinoid receptors (CB1 and CB2), are expressed in regions associated with migraine pathophysiology, such as the trigeminal system and the periaqueductal gray matter, suggesting a potential therapeutic target for migraine relief. 77-79

In pediatric studies, while direct research on cannabinoids for migraine prevention is limited, there is evidence supporting their use in managing other conditions like epilepsy, which often co-occurs with chronic headaches in children. A survey among pediatric neurologists indicated a cautious approach to prescribing cannabinoids for pediatric epilepsy, reflecting a broader hesitance in the medical community regarding off-label cannabinoid use in children. 80, 81 However, the therapeutic implications of cannabinoids in managing chronic pain conditions, including migraines, warrant further investigation, especially given the anecdotal reports of efficacy among pediatric patients. 81, 82

Mechanistically, cannabinoids exert their effects through various pathways. THC primarily acts on CB1 receptors, leading to analgesic effects, while CBD has a more complex interaction profile, including anti- inflammatory properties and modulation of neurotransmitter release. 83, 84 Studies have shown that cannabinoids can reduce the frequency and intensity of migraine attacks, with some patients reporting significant improvements in their condition after prolonged use. 85-87 The pharmacokinetics of cannabinoids can vary based on the formulation and route of administration, with inhalation being the most common method among users.88, 89

Despite the promising findings, the use of cannabinoids is not without side effects. Commonly reported adverse effects include dizziness, dry mouth, and alterations in mood or cognition, which can be particularly concerning in pediatric populations. 83, 90 Moreover, there is a risk of medication overuse headache (MOH) associated with frequent cannabinoid use, similar to other migraine treatments. 91 Dosing regimens vary widely, with some studies suggesting that lower doses may be more effective and better tolerated, emphasizing the need for personalized treatment approaches. 92

 

Corticosteroids

Corticosteroids have gained attention as a preventive treatment option for headaches and migraines, particularly in pediatric populations. The efficacy of corticosteroids in managing headache disorders has been supported by various studies, which highlight their potential benefits in reducing headache frequency and severity. For instance, a study focusing on the pediatric population demonstrated that corticosteroids, such as prednisone, were effective in alleviating chronic migraines, with significant improvements observed in headache-related disability and overall quality of life. 93 This finding underscores the importance of considering corticosteroids as a viable option in the management of headaches in children, especially when conventional treatments have proven insufficient.

The mechanism of action of corticosteroids in headache management primarily involves their potent anti- inflammatory properties. Corticosteroids function by inhibiting the release of pro-inflammatory cytokines and neuropeptides, such as calcitonin gene-related peptide (CGRP), which are implicated in the pathophysiology of migraines. This inhibition helps to mitigate the neurogenic inflammation that contributes to headache disorders, thereby reducing the frequency and intensity of headache episodes. Additionally, corticosteroids may exert effects on central pain processing pathways, further enhancing their efficacy in headache prevention. 94 This dual mechanism of action highlights the potential of corticosteroids to address both peripheral and central components of headache disorders.

In terms of dosing, various corticosteroids can be employed, each with specific dosing regimens tailored to the individual patient's needs. Prednisone is commonly prescribed at doses ranging from 60 to 100 mg per day for acute migraine management, with a tapering schedule often recommended to minimize withdrawal effects. Methylprednisolone is another corticosteroid that can be utilized, typically administered at doses of 40 mg to 80 mg for similar therapeutic effects. Dexamethasone, known for its long half-life, may also be employed, usually at doses ranging from 4 to 10 mg, depending on the clinical scenario. 95 The choice of corticosteroid and dosing regimen should be individualized, taking into account factors such as the severity of headaches, the patient's age, and any comorbid conditions.

Despite their therapeutic benefits, corticosteroids are associated with several side effects that warrant careful consideration. Common adverse effects include hypertension, hyperglycemia, weight gain, and potential psychological symptoms such as mood swings and anxiety. 96 In pediatric populations, specific concerns such as growth suppression and the risk of adrenal insufficiency must be taken into account when prescribing corticosteroids. The incidence of adverse effects is often dose-dependent, with higher doses correlating with an increased risk of complications. 97 Therefore, clinicians must weigh the potential benefits of corticosteroid therapy against the risks, particularly in children who may be more susceptible to the adverse effects of these medications.

Please click here to view complete article